CORAL GABLES, FL / ACCESSWIRE / September 5, 2018 / This month marks the beginning of "back to school season" and more importantly the start of the big push for reform as well as new policies in healthcare. In addition to this, there are a number of industry conferences that will be sure to breed more attention in the market for biotechnology and healthcare stocks moving forward.
Also in focus will be the next moves by Canada in anticipation for the October launch of legal marijuana sales across the country. With that, could also come new innovations for the delivery of CBD and THC for medical purposes. Over the course of recent history, a number of companies are harnessing the power of CBDs to address things like pain management and even cancer. This has also helped bring rise to more attention on numerous alternatives to advancements in things like oncology with big money being spent by industry leaders like Roche (RHHBY).
GT Biopharma (GTBP) recently gained attention after being one of only a few companies harnessing the power of NK cell technology. The NK market got its first big break in late August after Roche/Genentech invested nearly $100 million in up front funding with an option for $5 billion specifically into a company looking to also utilize NK cells.
GT Biopharma's Chairman and Chief Executive Officer Dr. Raymond Urbanski stated, that this latest event not only provides validation of the NK cell hypothesis but more specifically of the NK cell - engager concept. "GT Biopharma's innovative NK cell-engager platform incorporates IL-15, a potent activator and proliferator of NK cells. No other, including Affimed's, NK cell technology has this."
Shares of GT Biopharma have moved up by nearly 30% since hitting lows of $1.84 on August 22nd. GT Biopharma also recently announced the initiation of a combination trial of OXS-1550 and multi-billion dollar oncology drug, owned by a major Pharmaceutical Company.
This morning ProQR Therapeutics N.V. (PRQR) announced results from a planned interim analysis of its Phase 1/2 trial of QR-110 in patients with Leber's congenital amaurosis 10 (LCA10) due to the p.Cys998X mutation in the CEP290 gene. LCA10 typically leads to childhood blindness and has no available treatment options. According to the company, QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility courseand was well-tolerated with no serious adverse events. Additionally, a Phase 2/3 pivotal trial is expected to start in the first half of 2019
"The results of this interim analysis are encouraging and met our decision criteria to stop enrollment in this study and progress to a pivotal Phase 2/3 trial," said David Rodman, M.D., executive vice president of research and development of ProQR. "We observed a clinically meaningful improvement in vision in the treated eye as measured by both mechanistic and potential registration endpoints. Consistent with predictions based on our patient derived optic-cup models, improvement in visual function was observed as early as two months after treatment and was maximal and stable by three months and thereafter. We are very grateful to the study participants, their caregivers, and the investigators and their staff for the support in the development of QR-110 in this trial."
Shares rose to highs of more than $14 during pre market trading on Wednesday.
Cronos Group (CRON) is not necessarily working on any new oncology treatment but recent developments in lab science have lead to new innovations for cannabis use. The company recently announced a landmark partnership to produce cultured cannabinoids in unison with Ginkgo Bioworks Inc.
Using its platform technology for organism design and development, Ginkgo will complement Cronos Group's technologies for producing a full spectrum of cannabinoids. As part of this unprecedented deal, Cronos Group has agreed to issue a specific number of common shares in tranches subject to Ginkgo's achievement of certain production milestones.
"Legal cannabis is a multibillion-dollar industry with no signs of slowing down, but providers will need to innovate to keep up with demand for better products, including those taking advantage of rare and difficult to extract cannabinoids," said Jason Kelly, CEO and co-founder of Ginkgo Bioworks. "Engineering strains of yeast that can produce these cannabinoids via fermentation is a perfect fit for our organism design platform and we are excited to be working with Cronos Group as they lead the way to high-quality cannabinoid treatments."
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018, and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.